First-In-Human Study Evaluating a Novel Catheter Device in Subjects With Treatment-Resistant Hypertension
- Conditions
- Hypertension,Essential
- Interventions
- Device: Catheter-Based Carotid Body Ablation
- Registration Number
- NCT03314012
- Lead Sponsor
- Cibiem, Inc.
- Brief Summary
The carotid body is located at the bifurcation of the internal and external carotid arteries. It is a chemoreceptor that plays a role in the sympathetic nervous system and in the development and maintenance of hypertension. Hypertension is a major cardiovascular risk factor and is associated with coronary artery disease, stroke, chronic kidney disease, and heart failure.
The objective of this study is to assess the effectiveness and safety of a catheter-based system to ablate the carotid body and reduce blood pressure (BP) in patients with resistant hypertension and to confirm sustainability of the treatment benefits long-term as seen following surgical CB removal.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 39
- Mean office SBP ≥160 mmHg and DBP ≥90 mmHg during screen-in period
- Mean daytime systolic ABPM ≥135 mmHg during screen-in period
- Adherent to a stable drug regimen of three (3) or more anti-hypertensive medications of different classes (including one (1) diuretic), with no medication changes expected for at least six (6) months post-procedure
- No change in anti-hypertensive drug prescription (dose, number of medications, or class of medication) for at least six (6) weeks prior to enrollment
- Negative pregnancy test for women of child-bearing age
- Willingness and able to comply with follow-up requirements
- Signed informed consent
- Secondary causes of hypertension
- Calculated eGFR <30mL/min/1.73m2
- History of repeated episodes of hypoglycemic unawareness
- Morbid obesity, defined as Body Mass Index >40 kg/m2
- Severe obstructive sleep apnea (AHI > 35/hr.)
- Pacemaker and/or implantable defibrillators
- History of transient ischemic accident or cerebrovascular accident during six (6) months prior to screening
- History of acute heart failure, congestive heart failure (NYHA class III-IV), myocardial infarction, unstable angina, coronary bypass or coronary angioplasty during six (6) months prior to screening
- History of ipsilateral carotid endarterectomy treatment or ipsilateral carotid artery stenting
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Catheter-Based Carotid Body Ablation Catheter-Based Carotid Body Ablation All subjects undergo catheter-based ablation of the carotid body using the Cibiem Transvenous Ultrasound System (CTUS).
- Primary Outcome Measures
Name Time Method Mean reduction in 24-hour ambulatory systolic and diastolic blood pressure Baseline versus six months post-procedure Safety as assessed by incidence of major adverse events From procedure to one month post-procedure Safety assessed as the combined rate of major adverse events defined as all-causes of death, hospitalization for hypertensive crisis not related to confirmed non-adherence with anti-hypertensive medications, and any device or procedure-related serious adverse event.
- Secondary Outcome Measures
Name Time Method Composite rate of major adverse events At 6, 12, 18, and 24 months post-procedure Safety assessed as the combined rate of major adverse events defined as all-causes of death and hospitalization for hypertensive crisis not related to confirmed non-adherence with anti-hypertensive medications
Mean reduction in office systolic and diastolic blood pressure, and home systolic and diastolic blood pressure Baseline versus 3, 6, 12, 18, and 24 months Proportion of subjects with controlled blood pressure at 6, 12, 18, and 24 months post-procedure At 6, 12, 18, and 24 months Controlled blood pressure is defined as office blood pressure \<140/90 mmHg, mean 24-hr ABP \<130/80 mmHg, daytime ABP \<135/85 mmHg, and mean nighttime ABP \<120/70 mmHg
Ventricular morphometric improvements from cardiac MRI measurements Screening versus 12 and 24 months
Trial Locations
- Locations (7)
Na Homolce Hospital
🇨🇿Prague, Czechia
Clinic Cardiology and Angiology II
🇩🇪Bad Krozingen, Germany
Klinik für Innere Medizin III
🇩🇪Homburg, Germany
Cardiovascular Center Frankfurt (CVC Frankfurt)
🇩🇪Frankfurt, Germany
Royal Perth Hospital
🇦🇺Perth, Western Australia, Australia
Royal Adelaide Hospital
🇦🇺Adelaide, South Australia, Australia
Fiona Stanley Hospital
🇦🇺Murdoch, Western Australia, Australia